multi-stage genetic malaria vaccine (FMP2.1/AS02A) / GSK - LARVOL DELTA

Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies. (PubMed, Infection) - "Malaria vaccines protect against malaria infection in varying degrees, with severe side effects rarely occurring. Further research is required to improve vaccine efficacy and community involvement is needed to ensure successful widespread use in African communities."

Journal • Review • CNS Disorders • Epilepsy • Infectious Disease • Malaria • Pain

Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02 vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. (PubMed, Vaccine) - "Interestingly, AMA1 epitopes in infections from vaccinees had higher mean IC50, and consequently lower binding affinity, than epitopes generated from the control group (p = 0.01), suggesting that vaccine-induced selection impacted the immunological profile of the strains that pass through the sieve imposed by the vaccine-induced protection. These findings are consistent with a vaccine-derived sieve effect on the c1L region of AMA1 and suggest that sieve analyses of malaria vaccine trial samples targeted to epitopes identified in silico can help identify protective malaria antigens that may be efficacious if combined in a multivalent vaccine."

Clinical • Journal • Infectious Disease • Malaria